drug · antibody

EBGLYSS

updated 2mo ago

by $LLY ELI LILLY & Co🔗 ChEMBL

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for atopic eczema and eczematoid dermatitis and 5 investigational indications.

targets

Interleukin-13

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

EBGLYSS

trade names

Ebglyss

generic

LEBRIKIZUMAB-LBKZ

MOA

12.1 Mechanism of Action Lebrikizumab-lbkz is an IgG4 monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13 and allows IL-13 to bind to IL-13Rα1 but inhibits human IL-13 signaling through the IL-4Rα/IL-13Rα1 receptor complex. IL-13 is a naturally occurring cytokine that is involved in Type 2 inflammation, which is an important component in the pathogenesis of atopic dermatitis. Lebrikizumab-lbkz inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines and IgE. Lebrikizumab-lbkz-bound IL-13 can still bind IL-13Rα2 allowing subsequent internalization and natural clearance of IL-13.

indication

1 INDICATIONS AND USAGE EBGLYSS is indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. EBGLYSS ® is an interleukin-13 antagonist indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids. ( 1 )

EBGLYSS

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

🐶 often sniffed alongside